IMATINIB-EVEROL-CHORDOMA

NCT01407198 📎

Regimen

Experimental
Imatinib 400 mg PO QD + everolimus 2.5 mg PO QD continuous
Control
none (single-arm)

Population

Advanced chordoma progressing on imatinib monotherapy or with PDGFR pathway activation plus downstream mTOR pathway rationale

Key finding

Combination added modest incremental activity over imatinib alone, primarily in patients who had already progressed on single-agent imatinib — extended PFS by a few months. Supported mTOR co-inhibition hypothesis.

Source: PMID 30216418

Timeline

    Guideline citations

    • NCCN BONE (p.31)